Viewing Study NCT06082167


Ignite Creation Date: 2025-12-25 @ 12:54 AM
Ignite Modification Date: 2025-12-26 @ 1:45 PM
Study NCT ID: NCT06082167
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-17
First Post: 2023-10-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Exelixis
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module